These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 20701327)

  • 1. Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development.
    Fang JB; Robertson VK; Rawat A; Flick T; Tang ZJ; Cauchon NS; McElvain JS
    Mol Pharm; 2010 Oct; 7(5):1466-77. PubMed ID: 20701327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can dosage form-dependent food effects be predicted using biorelevant dissolution tests? Case example extended release nifedipine.
    Andreas CJ; Tomaszewska I; Muenster U; van der Mey D; Mueck W; Dressman JB
    Eur J Pharm Biopharm; 2016 Aug; 105():193-202. PubMed ID: 27322002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
    Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
    Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form.
    Jantratid E; De Maio V; Ronda E; Mattavelli V; Vertzoni M; Dressman JB
    Eur J Pharm Sci; 2009 Jun; 37(3-4):434-41. PubMed ID: 19491035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
    Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.
    Shono Y; Jantratid E; Janssen N; Kesisoglou F; Mao Y; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2009 Sep; 73(1):107-14. PubMed ID: 19465123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test.
    Heigoldt U; Sommer F; Daniels R; Wagner KG
    Eur J Pharm Biopharm; 2010 Sep; 76(1):105-11. PubMed ID: 20472059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of pantoprazole formulations in different dissolution apparatus using biorelevant medium.
    de Campos DR; Klein S; Zoller T; Vieria NR; Barros FA; Meurer EC; Coelho EC; Marchioretto MA; Pedrazzoli J
    Arzneimittelforschung; 2010; 60(1):42-7. PubMed ID: 20184226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissolution testing of modified release products with biorelevant media: An OrBiTo ring study using the USP apparatus III and IV.
    Reppas C; Vrettos NN; Dressman J; Andreas CJ; Miyaji Y; Brown J; Etherson K; Hanley S; Karkossa F; Karlsson E; Klein S; Maier GM; McAllister M; Mistry N; Rosenblatt K; Schäfer KJ; Smith KL; Tomaszewska I; Williams J; Winge F; Vertzoni M
    Eur J Pharm Biopharm; 2020 Nov; 156():40-49. PubMed ID: 32882421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biorelevant in-vitro performance testing of orally administered dosage forms.
    Reppas C; Vertzoni M
    J Pharm Pharmacol; 2012 Jul; 64(7):919-30. PubMed ID: 22686340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
    Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
    Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing biorelevant dissolution tests for lipid formulations: case example--lipid suspension of RZ-50.
    Jantratid E; Janssen N; Chokshi H; Tang K; Dressman JB
    Eur J Pharm Biopharm; 2008 Jun; 69(2):776-85. PubMed ID: 18226882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
    Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
    Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.
    Wagner C; Jantratid E; Kesisoglou F; Vertzoni M; Reppas C; B Dressman J
    Eur J Pharm Biopharm; 2012 Sep; 82(1):127-38. PubMed ID: 22652546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug release from matrix tablets: physiological parameters and the effect of food.
    Nokhodchi A; Asare-Addo K
    Expert Opin Drug Deliv; 2014 Sep; 11(9):1401-18. PubMed ID: 24970101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulating Different Dosing Scenarios for a Child-Appropriate Valproate ER Formulation in a New Pediatric Two-Stage Dissolution Model.
    Karkossa F; Krueger A; Urbaniak J; Klein S
    AAPS PharmSciTech; 2017 Feb; 18(2):309-316. PubMed ID: 27909943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.